Company / Net Income
Rein Therapeutics, Inc. Net Income History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$62.9M
FY2025
5-year range
-$62.9M / -$15.7M
FY2021-FY2025
Trend
-299.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income changed -300% YoY in FY2025, a notable deviation from the 8-year average annual change of -46%.
Based on SEC 10-K filings.
-$63M in FY2025.
Declined from -$27M to -$63M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, net income decreased 299.7% year-over-year.
- Peak net income was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -9.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$62.9M | -299.7% |
| FY2024 | -$15.7M | +42.4% |
| FY2023 | -$27.3M | +0.0% |
| FY2022 | -$27.3M | -29.2% |
| FY2021 | -$21.2M | +28.0% |
| FY2020 | -$29.4M | +6.9% |
| FY2019 | -$31.5M | -39.6% |
| FY2018 | -$22.6M | -75.5% |
| FY2017 | -$12.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026